Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Weiss Website

Jonathan M. Weiss, Ph.D.

Selected Publications

1)  Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ.
Effective chemoimmunotherapy with anti-TGFß antibody and cyclophosphamide in a mouse model of breast cancer.
PLoS ONE. 9: e85398, 2014.
2)  Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.
NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
Int. J. Cancer. 132: 9-18, 2013.
3)  Jiang Q, Weiss JM, Wiltrout RH.
A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment.
Oncoimmunology. 1: 115-117, 2012.
4)  Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.
Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.
Blood. 119: 3073-83, 2012.
5)  Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.
Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.
PLoS ONE. 7: e33303, 2012.
6)  Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.
Cancer Res. 71: 2718-27, 2011.
7)  Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, Murphy WJ.
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation.
Biol. Blood Marrow Transplant. 17: 1754-64, 2011.
8)  Chan T, Wiltrout RH, Weiss JM.
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.
Int. Immunopharmacol. 11: 879-89, 2011.
9)  Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, Wiltrout RH.
mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Cancer Res. 71: 4074-84, 2011.
10)  Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH.
The split personality of NKT cells in malignancy, autoimmune and allergic disorders.
Immunotherapy. 3: 1167-84, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 4/16/2014.